ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL), today announced preclinical data demonstrating the potential for miransertib (ARQ 092), it’s pan-AKT inhibitor, to treat PIK3CA driven vascular malformations (VMs) in a poster at the 2019 American Society of Human Genetics Annual Meeting. Studies conducted in an experimental mouse model show that miransertib prevents the formation of PIK3CA-driven VMs and shows high efficacy in regressing vascular growth in already developed VMs.